Prognostic markers in resectable non-small cell lung cancer

被引:49
作者
Strauss, GM
机构
[1] DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115
[2] HARVARD UNIV,SCH MED,BOSTON,MA
关键词
D O I
10.1016/S0889-8588(05)70441-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Numerous prognostic factors have been identified in patients with resectable non-small cell lung cancer (NSCLC) which may enable stratification of patients into subsets indicating risk of recurrence following complete resection. Such prognostic markers include a variety of clinico-pathologic factors such as tumor size, nodal status, and histopathologic variables. Several serum tumor markers have also proven useful. Moreover, a wide variety of; molecular markers have been described over the last decade, which can be classified as molecular genetic markers, metastatic propensity markers, differentiation markers, and proliferation markers. This article reviews those prognostic markers most likely to prove clinically useful from the perspective of guiding postresection treatment strategies in early stage NSCLC.
引用
收藏
页码:409 / &
页数:28
相关论文
共 104 条
[31]   PREOPERATIVE CARCINOEMBRYONIC ANTIGEN LEVEL AS A PROGNOSTIC INDICATOR IN RESECTED PRIMARY LUNG-CANCER [J].
ICARD, P ;
REGNARD, JF ;
ESSOMBA, A ;
PANEBIANCO, V ;
MAGDELEINAT, P ;
LEVASSEUR, P .
ANNALS OF THORACIC SURGERY, 1994, 58 (03) :811-814
[32]   IS T-FACTOR OF THE TNM STAGING SYSTEM A PREDOMINANT PROGNOSTIC FACTOR IN PATHOLOGICAL STAGE-I NON-SMALL-CELL LUNG-CANCER - A MULTIVARIATE PROGNOSTIC FACTOR-ANALYSIS OF 151 PATIENTS [J].
ICHINOSE, Y ;
HARA, N ;
OHTA, M ;
YANO, T ;
MAEDA, K ;
ASOH, H ;
KATSUDA, Y .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (01) :90-94
[33]   SITE OF RECURRENCE IN PATIENTS WITH STAGE-I AND STAGE-II CARCINOMA OF THE LUNG RESECTED FOR CURE [J].
IMMERMAN, SC ;
VANECKO, RM ;
FRY, WA ;
HEAD, LR ;
SHIELDS, TW .
ANNALS OF THORACIC SURGERY, 1981, 32 (01) :23-27
[34]  
ISHIDA T, 1993, CANCER RES, V53, P5000
[35]  
ISOBE H, 1990, CANCER, V65, P1391, DOI 10.1002/1097-0142(19900315)65:6<1391::AID-CNCR2820650624>3.0.CO
[36]  
2-K
[37]   C-ERBB-2 EXPRESSION AND CODON 12-K-RAS MUTATIONS BOTH PREDICT SHORTENED SURVIVAL FOR PATIENTS WITH PULMONARY ADENOCARCINOMAS [J].
KERN, JA ;
SLEBOS, RJC ;
TOP, B ;
RODENHUIS, S ;
LAGER, D ;
ROBINSON, RA ;
WEINER, D ;
SCHWARTZ, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :516-520
[38]  
KERN JA, 1990, CANCER RES, V50, P5184
[39]  
KUBIK A, 1986, CANCER, V57, P2428
[40]   Postresection irradiation for T2 N0 M0 non-small cell carcinoma: A prospective, randomized study [J].
Lafitte, JJ ;
Ribet, ME ;
Prevost, BM ;
Gosselin, BH ;
Copin, MC ;
Brichet, AH .
ANNALS OF THORACIC SURGERY, 1996, 62 (03) :830-834